Interim data showed 13 months’ median survival in 15 patients. Enrollment is complete; final data are expected mid-2027.
Cerenome, Inc. (CNSY) completed enrollment in its Phase 2 ReSPECT-GBM study for recurrent glioblastoma. Interim data showed a 13-month median survival. Topline data is expected mid-2027. The trial evaluates REYOBIQ, a radiotherapeutic designed to deliver targeted radiation. The company aims to discuss results with the FDA afterward.
How this was made
The 30-second read
Why it matters
The enrollment completion removes a key trial milestone risk, setting up a data‑driven catalyst in 2027.
Market read
Primary disclosure for a micro‑cap biotech; relevance mainly to CNS oncology investors.
What to watch
Potential regulatory scrutiny of radiotherapeutic delivery methods and competition from other CNS‑targeted therapies.
Background
Cerenome (NASDAQ:CNSY) is a CNS‑oncology company developing REYOBIQ, a radiotherapeutic delivered via convection‑enhanced delivery.
Ticker impact
Cerenome announced completion of enrollment for its Phase 2 ReSPECT-GBM trial and expects topline data in mid‑2027.
potential upside if Phase 2 data meet or exceed expectations; limited downside as the news is largely neutral.
The announcement is a primary disclosure for a micro‑cap biotech; the market typically reacts to data read‑outs, but no results are yet available.
Market effects
Adds a data point for the CNS oncology sector, but no immediate sector‑wide impact.
US biotech market may note the trial progress; limited broader regional effect.
Minimal global impact; relevance confined to investors in early‑stage oncology therapeutics.
Counterpoint
If investors over‑price the stock on speculative hopes, the lack of data until 2027 could lead to a correction.
Key entities
- CompanyCerenome, Inc.
NASDAQ‑listed CNS oncology biotech.
- ProductREYOBIQ™
Investigational radiotherapeutic for recurrent glioblastoma.
